Claims

What is claimed is:

1. A pharmaceutical formulation which comprises ceralasertib, dibasic calcium phosphate, microcrystalline cellulose, low-substituted hydroxypropyl cellulose and magnesium stearate.

2. A pharmaceutical formulation as claimed in claim 1 which comprises 30-50 % w/w ceralasertib.

3. A pharmaceutical formulation as claimed in any one of the preceding claims wherein the ceralasertib is ceralasertib Form A with an X-ray powder diffraction pattern with at least two specific peaks at about 2-theta = 21.2° and 17.2° as measured using CuKα radiation.

4. A pharmaceutical formulation as claimed in any one of the preceding claims which comprises 10-16% w/w anhydrous dibasic calcium phosphate.

5. A pharmaceutical formulation as claimed in any one of the preceding claims which comprises 30-40% w/w microcrystalline cellulose.

6. A pharmaceutical formulation as claimed in any one of the preceding claims which comprises 5-20% w/w low substituted hydroxypropyl cellulose.

7. A pharmaceutical formulation as claimed in any one of the preceding claims which comprises 0.5-2.5 % w/w magnesium stearate.

8. A pharmaceutical formulation as claimed in any one of the preceding claims which comprises 160mg of ceralasertib.

9. A pharmaceutical formulation as claimed in any one of claims 1 to 7 which comprises 120mg of ceralasertib.

10. A pharmaceutical formulation as claimed in any one of claims 1 to 7 which comprises 80mg of ceralasertib.

11. A pharmaceutical formulation as claimed in any one of the preceding claims which comprises:

40% w/w ceralasertib;

15% w/w anhydrous dibasic calcium phosphate;

33.5% w/w microcrystalline cellulose;

10% w/w low substituted hydroxypropyl cellulose; and

1.5% w/w magnesium stearate.

12 A pharmaceutical formulation as claimed in any one of the preceding claims that is a tablet formulation.

13. A pharmaceutical formulation as claimed in claim 12 additionally comprising a coloured film coating.

14. A pharmaceutical formulation as claimed in any one of the preceding claims for use as a medicament.

15. Use of the pharmaceutical formulation as claimed in any one of claims 1-13 in the manufacture of a medicament for producing an ATR inhibitory effect in a warm-blooded animal, such as man, wherein an effective amount of the pharmaceutical formulation is to be administered to said animal.

16. The use of a pharmaceutical formulation as claimed in any one of claims 1-13 in the manufacture of a medicament for the treatment of cancer in a warm-blooded animal such as man.

17. A pharmaceutical formulation as claimed in any one of claims 1-13 for use in the treatment of breast cancer, triple negative breast cancer, gastric cancer, chronic lymphocytic leukaemia, head and neck squamous cell carcinoma, non-small cell lung cancer, ovarian cancer, non-Hodgkin’s lymphoma, small cell lung cancer, or melanoma.

18. Use of the pharmaceutical formulation as claimed in any one of claims 1-13 in the manufacture of a medicament for the treatment of breast cancer, triple negative breast cancer, gastric cancer, chronic lymphocytic leukaemia, head and neck squamous cell carcinoma, non-

small cell lung cancer, ovarian cancer, non-Hodgkin’s lymphoma, small cell lung cancer, or melanoma.